
    
      This is a multicenter, international, open-label, single arm, Phase 2 study designed to
      evaluate the efficacy and safety of ibrutinib in subjects with relapsed/refractory CLL or SLL
      with del 17p. All subjects will receive ibrutinib until disease progression or unacceptable
      toxicity occurs.
    
  